Yoshiyuki Yamamoto, Hiroki Yukami, Tatsuro Yamaguchi, Hisatsugu Ohori, Sachiko Nagasu, Yoshinori Kagawa, Naotoshi Sugimoto, Hiromichi Sonoda, Kentaro Yamazaki, Atsuo Takashima, et al. Real-world outcomes of FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer: the JSCCR-TRIPON study. International journal of clinical oncology. 2024
Kentaro Sudo, Yoshiaki Nakamura, Makoto Ueno, Masayuki Furukawa, Nobumasa Mizuno, Yasuyuki Kawamoto, Naohiro Okano, Kumiko Umemoto, Akinori Asagi, Masato Ozaka, et al. Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer. British journal of cancer. 2024
Hiroshi Nakatsumi, Yoshito Komatsu, Kazuaki Harada, Yasuyuki Kawamoto, Satoshi Yuki, Kentaro Sawada, Atsushi Ishiguro, Susumu Sogabe, Takayuki Ando, Yusuke Sasaki, et al. A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801. International journal of cancer. 2024
Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, Yoshito Komatsu, Makoto Ueno, Satoshi Kobayashi, Masafumi Ikeda, Mitsuhito Sasaki, Junji Furuse, Naohiro Okano, et al. Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2-Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2024. JCO2302010
Yasuyuki Kawamoto, Chigusa Morizane, Yoshito Komatsu, Shunsuke Kondo, Makoto Ueno, Satoshi Kobayashi, Masayuki Furukawa, Lingaku Lee, Taroh Satoh, Daisuke Sakai, et al. Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B. Future oncology (London, England). 2024. 1-7
T. Kawakami, K. Yamazaki, H. Go, T. Masuishi, Y. Kawamoto, K. Kato, R. Kumanishi, K. Sawada, H. Shirasu, S. Yuki, et al. The impact of late-line treatment on overall survival (OS) from the initiation of first-line chemotherapy (CT) for patients (pts) with metastatic colorectal cancer (mCRC): Updated analysis. ANNALS OF ONCOLOGY. 2020. 31. S433-S434